The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pet Biopharmaceuticals-Global Market Insights and Sales Trends 2024
Synopsis
The global Pet Biopharmaceuticals market size is expected to reach US$ 19590 million by 2029, growing at a CAGR of 4.7% from 2023 to 2029. The market is mainly driven by the significant applications of Pet Biopharmaceuticals in various end use industries. The expanding demands from the Prevention and Treatment, are propelling Pet Biopharmaceuticals market. Antiparasitic, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biological Products segment is estimated at % CAGR for the next seven-year period.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 47%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pet Biopharmaceuticals, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pet Biopharmaceuticals market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pet Biopharmaceuticals market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pet Biopharmaceuticals sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pet Biopharmaceuticals covered in this report include Zoetis, Boehringer Ingelheim, Merck, Elanco, Virbac, Dechra Veterinary Products, Ceva, Vetoquinol and Ouro Fino Saude, etc.
The global Pet Biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Zoetis
Boehringer Ingelheim
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Chopperlvya Animal Health
CAHIC
Global Pet Biopharmaceuticals market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pet Biopharmaceuticals market, Segment by Type:
Antiparasitic
Biological Products
Antibacterial
Others
Global Pet Biopharmaceuticals market, by Application
Prevention
Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pet Biopharmaceuticals companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Pet Biopharmaceuticals market size is expected to reach US$ 19590 million by 2029, growing at a CAGR of 4.7% from 2023 to 2029. The market is mainly driven by the significant applications of Pet Biopharmaceuticals in various end use industries. The expanding demands from the Prevention and Treatment, are propelling Pet Biopharmaceuticals market. Antiparasitic, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Biological Products segment is estimated at % CAGR for the next seven-year period.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 47%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pet Biopharmaceuticals, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pet Biopharmaceuticals market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pet Biopharmaceuticals market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pet Biopharmaceuticals sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pet Biopharmaceuticals covered in this report include Zoetis, Boehringer Ingelheim, Merck, Elanco, Virbac, Dechra Veterinary Products, Ceva, Vetoquinol and Ouro Fino Saude, etc.
The global Pet Biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Zoetis
Boehringer Ingelheim
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Chopperlvya Animal Health
CAHIC
Global Pet Biopharmaceuticals market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pet Biopharmaceuticals market, Segment by Type:
Antiparasitic
Biological Products
Antibacterial
Others
Global Pet Biopharmaceuticals market, by Application
Prevention
Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pet Biopharmaceuticals companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pet Biopharmaceuticals
1.1 Pet Biopharmaceuticals Market Overview
1.1.1 Pet Biopharmaceuticals Product Scope
1.1.2 Pet Biopharmaceuticals Market Status and Outlook
1.2 Global Pet Biopharmaceuticals Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pet Biopharmaceuticals Market Size by Region (2018-2029)
1.4 Global Pet Biopharmaceuticals Historic Market Size by Region (2018-2023)
1.5 Global Pet Biopharmaceuticals Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pet Biopharmaceuticals Market Size (2018-2029)
1.6.1 North America Pet Biopharmaceuticals Market Size (2018-2029)
1.6.2 Europe Pet Biopharmaceuticals Market Size (2018-2029)
1.6.3 Asia-Pacific Pet Biopharmaceuticals Market Size (2018-2029)
1.6.4 Latin America Pet Biopharmaceuticals Market Size (2018-2029)
1.6.5 Middle East & Africa Pet Biopharmaceuticals Market Size (2018-2029)
2 Pet Biopharmaceuticals Market by Type
2.1 Introduction
2.1.1 Antiparasitic
2.1.2 Biological Products
2.1.3 Antibacterial
2.1.4 Others
2.2 Global Pet Biopharmaceuticals Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pet Biopharmaceuticals Historic Market Size by Type (2018-2023)
2.2.2 Global Pet Biopharmaceuticals Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pet Biopharmaceuticals Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pet Biopharmaceuticals Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pet Biopharmaceuticals Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pet Biopharmaceuticals Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pet Biopharmaceuticals Revenue Breakdown by Type (2018-2029)
3 Pet Biopharmaceuticals Market Overview by Application
3.1 Introduction
3.1.1 Prevention
3.1.2 Treatment
3.2 Global Pet Biopharmaceuticals Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pet Biopharmaceuticals Historic Market Size by Application (2018-2023)
3.2.2 Global Pet Biopharmaceuticals Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pet Biopharmaceuticals Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pet Biopharmaceuticals Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pet Biopharmaceuticals Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pet Biopharmaceuticals Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pet Biopharmaceuticals Revenue Breakdown by Application (2018-2029)
4 Pet Biopharmaceuticals Competition Analysis by Players
4.1 Global Pet Biopharmaceuticals Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pet Biopharmaceuticals as of 2022)
4.3 Date of Key Players Enter into Pet Biopharmaceuticals Market
4.4 Global Top Players Pet Biopharmaceuticals Headquarters and Area Served
4.5 Key Players Pet Biopharmaceuticals Product Solution and Service
4.6 Competitive Status
4.6.1 Pet Biopharmaceuticals Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Zoetis
5.1.1 Zoetis Profile
5.1.2 Zoetis Main Business
5.1.3 Zoetis Pet Biopharmaceuticals Products, Services and Solutions
5.1.4 Zoetis Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.1.5 Zoetis Recent Developments
5.2 Boehringer Ingelheim
5.2.1 Boehringer Ingelheim Profile
5.2.2 Boehringer Ingelheim Main Business
5.2.3 Boehringer Ingelheim Pet Biopharmaceuticals Products, Services and Solutions
5.2.4 Boehringer Ingelheim Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.2.5 Boehringer Ingelheim Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Pet Biopharmaceuticals Products, Services and Solutions
5.3.4 Merck Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.3.5 Elanco Recent Developments
5.4 Elanco
5.4.1 Elanco Profile
5.4.2 Elanco Main Business
5.4.3 Elanco Pet Biopharmaceuticals Products, Services and Solutions
5.4.4 Elanco Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.4.5 Elanco Recent Developments
5.5 Virbac
5.5.1 Virbac Profile
5.5.2 Virbac Main Business
5.5.3 Virbac Pet Biopharmaceuticals Products, Services and Solutions
5.5.4 Virbac Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.5.5 Virbac Recent Developments
5.6 Dechra Veterinary Products
5.6.1 Dechra Veterinary Products Profile
5.6.2 Dechra Veterinary Products Main Business
5.6.3 Dechra Veterinary Products Pet Biopharmaceuticals Products, Services and Solutions
5.6.4 Dechra Veterinary Products Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.6.5 Dechra Veterinary Products Recent Developments
5.7 Ceva
5.7.1 Ceva Profile
5.7.2 Ceva Main Business
5.7.3 Ceva Pet Biopharmaceuticals Products, Services and Solutions
5.7.4 Ceva Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.7.5 Ceva Recent Developments
5.8 Vetoquinol
5.8.1 Vetoquinol Profile
5.8.2 Vetoquinol Main Business
5.8.3 Vetoquinol Pet Biopharmaceuticals Products, Services and Solutions
5.8.4 Vetoquinol Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.8.5 Vetoquinol Recent Developments
5.9 Ouro Fino Saude
5.9.1 Ouro Fino Saude Profile
5.9.2 Ouro Fino Saude Main Business
5.9.3 Ouro Fino Saude Pet Biopharmaceuticals Products, Services and Solutions
5.9.4 Ouro Fino Saude Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.9.5 Ouro Fino Saude Recent Developments
5.10 Norbrook
5.10.1 Norbrook Profile
5.10.2 Norbrook Main Business
5.10.3 Norbrook Pet Biopharmaceuticals Products, Services and Solutions
5.10.4 Norbrook Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.10.5 Norbrook Recent Developments
5.11 Jindun
5.11.1 Jindun Profile
5.11.2 Jindun Main Business
5.11.3 Jindun Pet Biopharmaceuticals Products, Services and Solutions
5.11.4 Jindun Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.11.5 Jindun Recent Developments
5.12 Chopperlvya Animal Health
5.12.1 Chopperlvya Animal Health Profile
5.12.2 Chopperlvya Animal Health Main Business
5.12.3 Chopperlvya Animal Health Pet Biopharmaceuticals Products, Services and Solutions
5.12.4 Chopperlvya Animal Health Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.12.5 Chopperlvya Animal Health Recent Developments
5.13 CAHIC
5.13.1 CAHIC Profile
5.13.2 CAHIC Main Business
5.13.3 CAHIC Pet Biopharmaceuticals Products, Services and Solutions
5.13.4 CAHIC Pet Biopharmaceuticals Revenue (US$ Million) & (2018-2023)
5.13.5 CAHIC Recent Developments
6 North America
6.1 North America Pet Biopharmaceuticals Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Pet Biopharmaceuticals Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pet Biopharmaceuticals Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pet Biopharmaceuticals Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pet Biopharmaceuticals Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pet Biopharmaceuticals Market Dynamics
11.1 Pet Biopharmaceuticals Industry Trends
11.2 Pet Biopharmaceuticals Market Drivers
11.3 Pet Biopharmaceuticals Market Challenges
11.4 Pet Biopharmaceuticals Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
